Clinical Trial Update: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). [Phase 2]

View source ↗

Summary

DETECT IV is a Phase 2 clinical trial investigating HER2-negative metastatic breast cancer with persisting HER2-negative circulating tumor cells (CTCs). The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Prof. Wolfgang Janni | Conditions: HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells | Phase 2 | Status: COMPLETED